Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
- Conditions
- AML
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 60
- Registration Number
- NCT06744556
VHAG in Treating R/R T-ALL/LBL
- Conditions
- Acute T Lymphpblastic Leukemia/Lymphoma
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 50
- Registration Number
- NCT06742463
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
- Conditions
- LymphomaPeripheral T Cell LymphomaAngioimmunoblastic T-cell LymphomaEnteropathy-Associated T-Cell LymphomaMonomorphic Epitheliotropic Intestinal T-Cell Lymphoma
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Eric Jacobsen, MD
- Target Recruit Count
- 24
- Registration Number
- NCT06692452
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy
- Conditions
- LeukemiaLeukemia, MyeloidLeukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Affiliated Hospital of Nantong University
- Target Recruit Count
- 83
- Registration Number
- NCT06643962
- Locations
- 🇨🇳
Affiliated hospital of Nantong University, Nantong, Jiangsu, China
Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML
- Conditions
- Relapsed/Refractory Acute Myeloid LeukaemiaMyeloid Malignancy
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 20
- Registration Number
- NCT06621212
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 42
- Registration Number
- NCT06621199
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation
- Conditions
- FLT3 Gene MutationAML
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-20
- Target Recruit Count
- 36
- Registration Number
- NCT06561880
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
- Conditions
- Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 20
- Registration Number
- NCT06561152
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
- Conditions
- Precursor B-Cell Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 20
- Registration Number
- NCT06554626
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Hospital Municipal São José
- Target Recruit Count
- 100
- Registration Number
- NCT06537843
- Locations
- 🇧🇷
Hospital Ophir Loyola, Belem, Brazil
🇧🇷Hospital de Clínicas da UFPR, Curitiba, Brazil
🇧🇷Hospital Amaral Carvalho, Jaú, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.